82
Health & Science19h 21m ago

The FDA has granted accelerated approval to donanemab, a monoclonal antibody treatment designed to slow the progression of early-stage Alzheimer’s disease.

Silver Spring, Maryland, USA

Who
U.S. Food and Drug Administration (FDA) / Eli Lilly
What
The FDA has granted accelerated approval to donanemab, a monoclonal antibody treatment designed to slow the progression of early-stage Alzheimer’s disease.
When
Mon, 08 Jun 2026 14:40:07 GMT · 19h 21m ago
Where
Silver Spring, Maryland, USA · 39.00°N, 77.03°W
Why
Clinical trial data demonstrated a 35% slowing of cognitive decline over 18 months by effectively clearing amyloid plaques from the brain.
The Frontline Impact

How this affects you

This expands treatment options for millions of patients in the early stages of dementia, though it requires strict monitoring for side effects like brain swelling.

Story chain

1 event in this thread
No related history yet — this is the origin event.

Verified Sources & Citations

Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.